1. Home
  2. NRDS vs IRWD Comparison

NRDS vs IRWD Comparison

Compare NRDS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

HOLD

Current Price

$8.36

Market Cap

720.4M

Sector

Technology

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.54

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRDS
IRWD
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
720.4M
663.6M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
NRDS
IRWD
Price
$8.36
$3.54
Analyst Decision
Buy
Buy
Analyst Count
5
3
Target Price
$15.00
$7.67
AVG Volume (30 Days)
809.0K
2.1M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
68.42
1400.00
EPS
0.29
0.24
Revenue
$836,600,000.00
$298,276,000.00
Revenue This Year
$10.13
$57.95
Revenue Next Year
$7.11
$4.39
P/E Ratio
$29.31
$15.25
Revenue Growth
21.67
8.88
52 Week Low
$7.33
$0.66
52 Week High
$16.24
$5.78

Technical Indicators

Market Signals
Indicator
NRDS
IRWD
Relative Strength Index (RSI) 44.34 46.65
Support Level $7.82 $3.08
Resistance Level $8.81 $3.95
Average True Range (ATR) 0.31 0.19
MACD 0.10 0.04
Stochastic Oscillator 54.27 59.69

Price Performance

Historical Comparison
NRDS
IRWD

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: